Accepted for Publication: October 10, 2014.
Published Online: February 18, 2015. doi:10.1001/jamadermatol.2014.4305.
Study concept and design: Margolis, Hoffstad, Bilker.
Acquisition, analysis, or interpretation of data: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Margolis, Hoffstad, Bilker.
Obtained funding: Margolis.
Administrative, technical, or material support: Hoffstad.
Study supervision: Margolis.
Conflict of Interest Disclosures: Dr Margolis reported serving on a data safety monitoring board for the Astellas Pharma Inc APPLES study (A Pediatric Longitudinal Evaluation to Assess the Long-term Safety of Protopic for the Treatment of Atopic Dermatitis). No other disclosures were reported.
Funding/Support: This study and the PEER study were funded by Valeant Pharmaceuticals International through a grant to the Trustees of the University of Pennsylvania.
Role of the Funder/Sponsor: Ms Raimondo is an employee of Valeant Pharmaceuticals International. She participated in the review and approval of the manuscript. Otherwise, the funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.